CHENGDU YACHT BIO-TECHNOLOGY CO LTD

Overview

CHENGDU YACHT BIO-TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 11 active FDA Type II Drug Master Files, covering ANIDULAFUNGIN; CASPOFUNGIN ACETATE; DALBAVANCIN HYDROCHLORIDE; DAPTOMYCIN; EVEROLIMUS; MUPIROCIN.

API / Drug Master Files

CHENGDU YACHT BIO-TECHNOLOGY CO LTD holds 11 active (11 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• ANIDULAFUNGINActive2025-11-25
• PIMECROLIMUSActive2025-09-19
• MUPIROCINActive2025-09-19
• POLYMYXIN B SULFATEActive2025-03-11
• DALBAVANCIN HYDROCHLORIDEActive2024-12-13
• TACROLIMUSActive2024-10-13
• EVEROLIMUSActive2024-04-01
• CASPOFUNGIN ACETATEActive2019-11-19
• DAPTOMYCINActive2018-08-08
• DAPTOMYCINActive2016-05-26
• EVEROLIMUSActive2015-06-05

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CHENGDU YACHT BIO-TECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.